SHPH
Shuttle Pharmaceuticals Holdings Inc
$
3.420
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.800
Open
3.640
VWAP
3.57
Vol
40.21K
Mkt Cap
3.66M
Low
3.370
Amount
143.42K
EV/EBITDA(TTM)
--
Total Shares
16.79M
EV
-31.24K
EV/OCF(TTM)
--
P/S(TTM)
--
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
Show More
Valuation Metrics
The current forward P/E ratio for Shuttle Pharmaceuticals Holdings Inc (SHPH.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Shuttle Pharmaceuticals Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+113.11%
-2.95M
Operating Profit
FY2025Q1
YoY :
+76.37%
-3.05M
Net Income after Tax
FY2025Q1
YoY :
-63.62%
-7.60
EPS - Diluted
FY2025Q1
YoY :
+103.94%
-2.53M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
2.6K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
2.6K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SHPH News & Events
Events Timeline
2025-06-12 (ET)
2025-06-12
12:01:37
Shuttle Pharmaceuticals says reverse stock split to become effective June 16
2025-06-12
08:40:46
Shuttle Pharmaceuticals announces 25-for-1 proposed reverse stock split
2025-06-04 (ET)
2025-06-04
16:08:28
Shuttle Pharmaceuticals appoints George Scorsis as chairman
Sign Up For More Events
Sign Up For More Events
News
8.5
06-24NewsfilterShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
9.0
06-15TipRanksUpcoming Stock Splits This Week (June 16 to June 20) – Stay Invested
2.0
06-12NewsfilterShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
Sign Up For More News
People Also Watch
SCNI
Scinai Immunotherapeutics Ltd
1.520
USD
-1.30%
GNLN
Greenlane Holdings Inc
3.260
USD
+6.19%
ICON
Icon Energy Corp
2.270
USD
-1.30%
AQB
AquaBounty Technologies Inc
0.748
USD
+1.22%
TRNR
Interactive Strength Inc
4.210
USD
0.00%
BQ
Boqii Holding Ltd
2.530
USD
-3.44%
SISI
Shineco Inc
6.570
USD
-10.00%
QLGN
Qualigen Therapeutics Inc
1.820
USD
-1.62%
FAQ
What is Shuttle Pharmaceuticals Holdings Inc (SHPH) stock price today?
The current price of SHPH is 3.42 USD — it has decreased -2.84 % in the last trading day.
What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s business?
What is the price predicton of SHPH Stock?
What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s revenue for the last quarter?
What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Shuttle Pharmaceuticals Holdings Inc (SHPH)'s fundamentals?
How many employees does Shuttle Pharmaceuticals Holdings Inc (SHPH). have?